ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana +10 more·2016·Nature Communications

DOI 10.1038/ncomms13837

Cited by (386)

Items 301–386 of 386

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe
Juliet Guay, Hellen Kuasne, Catherine Chabot, Kathryn Bozek, Yasamin Majedi, Marguerite Buchanan, Adriana Aguilar‐Mahecha, Eric Bareke, Benjamin Ulmer, Tim Kong et al. · 2026 · Cancer Research Communications
Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics
Maria Farooq, Michael Jon Pishvaian · 2025 · Seminars in Radiation Oncology
Oxidative stress and cancer metabolism: From pathogenesis to therapeutic opportunities
Tejas Girish Agnihotri, Shyam Sudhakar Gomte, Biswajit Rout, Vasu Peddinti, Sandeep Kr Maharana, Devaraj Yallappa, Aakanchha Jain · 2025 · Elsevier eBooks
Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies
Sunisa Prasopporn, Gunya Sittithumcharee, Jantappapa Chanthercrob, Somchai Limsrichamrern, Arada Hirankitti, Pimkanya More-Krong, Sakda Sathirareuangchai, Amphun Chaiboonchoe, Somponnat Sampattavanich, Seiji Okada et al. · 2025 · Scientific Reports
Therapeutic opportunities in EBV-positive gastric cancer subtypes
Hasan Al-Sattar, Richard Peter Owen, Amir Mashia Jaafari, Abhishek Saha, Koushikk Ayyappan, Aruni Ghose, Stergios Boussios, Sola Michael Adeleke · 2025 · Therapeutic Advances in Medical Oncology
Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models
Ma Shuai, Yingying Han, Rui Cai Gu, Qi Chen, Qiushi Guo, Yuan Yue, Cheng Cao, Ling Liu, Zhenzhen Yang, Yan Qin et al. · 2025 · Journal of Clinical Investigation
Context-dependent synthetic lethality — an emerging precision therapeutic approach
Liang Chang, Katharin L. Shaw, Francisca Vázquez, William R. Sellers · 2026 · Nature reviews. Cancer
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance
Valentina Morgera, Antonia Feola, Antonella Romano, Maria Vittoria Napoli, Armando Gabrielli, Vittorio Enrico Avvedimento, Antonio Porcellini, Antonio Pezone · 2026 · Experimental Hematology and Oncology
Role of AT‐rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives
Xiaofang Zhang, Youzhi Zhang, Qiaoyun Zhang, Mengyao Lu, Yuan Chen, Xiaoyu Zhang, Peng Zhang · 2023 · Journal of Cellular and Molecular Medicine
Molecular interplay of ARID1A in gastrointestinal cancers
Alina Athar, Ejaj Ahmad, Pinki Bera, Md Abu Nasar, Khalid Imtiyaz, Mohammad Moshahid Alam Rizvi, Sundeep Singh Saluja · 2025 · Medical Oncology
Precision Medicine Based on Next-Generation Sequencing and Master Controllers
Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2018 · Springer eBooks
Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy
Ryan Nelson, Rutika Jitesh Mehta, Howard L. McLeod, Christine Marie Walko · 2019 · JCO Precision Oncology
Disparity in the era of personalized medicine for epithelial ovarian cancer
Michael-John Devlin, Rowan E. Miller · 2023 · Therapeutic Advances in Medical Oncology
Genomic Instability in Kidney Cancer: Etiologies and Treatment Opportunities
Patrick Glen Pilie · 2019 · Kidney Cancer
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
Fiona A. Simpkins, Yasuto Kinose, Haineng Xu, Hyoung Kim, Sushil Kumar, Xiaoyin Shan, Erin Geroge, Xiaolei Wang, Sergey Medvedev, Benjamin I. Ferman et al. · 2023 · Research Square
DNA Damage Repair Inhibitor for Breast Cancer Treatment
Ahrum Min, Kyung-Hun Lee, Seock‐Ah Im · 2021 · Advances in experimental medicine and biology
A Rare Case of Rhabdoid Pancreatic Carcinoma: Prolonged Disease-Free Survival Following Upfront Resection and Adjuvant Chemotherapy
Gabriel Land, Benjamin Van Haeringen, Caroline Louise Cooper, Vladimir Andelkovic, Thomas O’Rourke · 2023 · Cureus
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng, Dhruv Chachad, Timothy P. DiPeri, Bailiang Wang, Stephen M. Scott et al. · 2025 · Molecular Cancer Therapeutics
Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy
Delong Liu, Boning Liu, Ri‐Yao Yang, Jiaming Song, Qihui Chen, Zhiguo Liu, Shunjie Xiong, Shasha Shi, Mien‐Chie Hung, Linlin Sun · 2026 · Cancer Letters
Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia
Ping Li, Haiyan Ren, Xinyan Lan, Junfei Li, Zhi Liu, Huashuo Liu, Zhijie Zheng, Tianyan Zeng, Peili Wang, Mingyang Sun et al. · 2026 · RSC Medicinal Chemistry
Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation
Wan Shu, Kejun Dong, Xiaoyu Shen, Xing Zhou, Jiarui Zhang, Shuyang Yu, Shuangshuang Cheng, Tangansu Zhang, Guanxiao Chen, Jun Zhang et al. · 2026 · Molecular Cancer
Synthetic rescue in Saccharomyces cerevisiae: Concepts, large-scale genetic mapping, and functional implications
Ji Eun Choi, Woo‐Hyun Chung · 2026 · The Journal of Microbiology
Molecular profile and targeted therapies for ovarian clear cell ovarian cancer
Manavi Sachdeva, D TAN · 2026 · Therapeutic Advances in Medical Oncology
Molecular mechanisms of KMT2C alterations in gastrointestinal cancers: enhancer network destabilization, lineage plasticity, and clinical translation
Xintao Zeng, Pei Yang, Tao Wang, Ruizi Shi, Chuan Qin, Lun Zhang, Ting Jiang, Xi Chen, Hua Luo, Jihong Wei et al. · 2026 · Frontiers in Immunology
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Rahul Raj Aggarwal, Antoîne Italiano, Susan M. Domchek, Oscar B. Goodman, Sophie C. Postel-Vinay, Jesús García-Donás, Tanya Barauskas Dorff, Zachery Roger Reichert, Armelle Vinceneux, Neal D. Shore et al. · 2026 · Cancer Research Communications
Targeting p53 in Cancer: Functional States, Therapeutic Strategies, and Clinical Progress
Anais Saunders, Joshua Barkin, Anthony Nicholas Karnezis, Jeremy Chien · 2026 · Cancers
Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
Sisi Qin, Jeongmin An, Wang Qiao, Xu Zhichao, Tang Siyao, Gayoung Seo, Fei Zhao, Wootae Kim · 2026 · Biomedicine & Pharmacotherapy
Targeting DNA Damage Response Pathways for Cancer Therapy
Picheswara Rao Polu, Manish Vyas · 2026 · Springer eBooks
Molecular Landscape in Ovarian Clear Cell Carcinoma
Nozomu Yanaihara, Aikou Okamoto · 2021 · Current human cell research and applications
Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers
Rosa Falcone, Marco Filetti, Pasquale Lombardi, Valeria Altamura, Francesco Paroni Sterbini, Giovanni Scambia, Gennaro Daniele · 2023 · Exploration of Targeted Anti-tumor Therapy
Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas
Sonikpreet Aulakh, Joanne Xiu, Andrew C. Hinton, Sourat Darabi, Michael J. Demeure, Soma Sengupta, Santosh Kesari, David M. Ashley, Ashley Love Sumrall, Michael Glantz et al. · 2024 · Neuro-Oncology Advances
Explore the correlation between ARID1A and ANXA1 expressions in gastric cancer
Leo Yamada, Motonobu Saito, Aung Kyi Thar Min, Katsuharu Saito, Koji Kase, Hisashi Onozawa, Hirokazu Okayama, Shotaro Fujita, Hisahito Endo, Wataru Sakamoto et al. · 2019 · Annals of Cancer Research and Therapy
Emerging precision therapies for gastric cancer
Elizabeth Cartwright, Avani Athauda, Ian Chau · 2020 · Expert Review of Precision Medicine and Drug Development
PDAC Subtypes/Stratification
Holly Brunton, Giuseppina Caligiuri, Gareth J. Inman, Peter J. Bailey · 2020 · Molecular and translational medicine
Decreased expression of ARID1A invasively downregulates the expression of ribosomal proteins in hepatocellular carcinoma.
Jing Zhao, Weiran Xu, Yu Zhang, Xiaoming Lv, Yi-Ran Chen, Gao-Da Ju, Fan Yang, Li Lin, Xiaosong Rao, Ziwei Guo et al. · 2021 · Biomarkers in Medicine
Arid1a Haploinsufficiency Initiates Neural Crest Transformation in a Mouse Model of Mycn-driven Neuroblastoma
Kirby A. Wallace · 2020
Thymidine rescues ATR kinase inhibition induced deoxyuridine contamination in genomic DNA, cell death, and Type 1 interferon expression
Norie Sugitani, Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva, Sandra Schamus-Haynes, Yiyang Wang, Drake Palmer, Hatice U. Osmanbeyoglu et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
Integrated multiomic profiling reveals SWI/SNF subunit-specific pathway alterations and targetable vulnerabilities
Jorge Bretones Santamarina, Clémence Astier, Marlène Garrido, Leo Colmet Daage, Theodoros I. Roumeliotis, Elodie Anthony, Mercedes Pardo, Marianne Chasseriaud, Pierre Gestraud, C. Duong-Ngo et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
ARID1A and ARID1B preserve B cell identity, prevent myeloid transformation and reveal therapeutic vulnerabilities
Phyo Nay Lin, Joohyung Park, Yoon-A Kang, George P. Souroullas · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade
Zhigui Li, Shijun Mi, Oloruntoba Ismail Osagie, Jing Ji, Chia‐Ping Huang Yang, Melissa Schwartz, Pei Hui, Gloria Shining Huang · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
Exploiting genomic instability as an Achilles’ heel in cancer
Sergi Guerrero Llobet · 2021
Faculty Opinions recommendation of Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors.
Scott H. Kaufmann · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Precision Medicine Based on Next Generation Sequencing and Master Controllers
Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2017 · Springer eBooks
Chromatin regulators in DNA replication and genome stability maintenance during S-phase
Anastas G. Gospodinov, Stefka Dzhokova, Maria Petrova, Iva Ugrinova · 2023 · Advances in protein chemistry and structural biology
Data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Roman M. Chabanon, Daphné Morel, Thomas Eychenne, Leo Colmet Daage, Ilirjana Bajrami, Nicolas Dorvault, Marlène Garrido, Cornelia Meisenberg, Andrew E. Lamb, C. Duong-Ngo et al. · 2023
Data from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Marta J. Llorca-Cardeñosa, Lauren I. Aronson, Dragomir B. Krastev, Jadwiga Nieminuszczy, John J. Alexander, Feifei Song, Małgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann et al. · 2023
Data from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Hideo Tomihara, Federica Carbone, Luigi Perelli, Justin Kwang-Lay Huang, Melinda Soeung, Johnathon Lynn Rose, Frederick Scott Robinson, Yonathan Lissanu Deribe, Ningping Feng, Mitsunobu Takeda et al. · 2023
Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
Patrick C. O’Leary, Huadong Chen, Yagmur Umay Doruk, Tess Williamson, Benjamin J. Polacco, Andrew S. McNeal, Tanushree Shenoy, Nupura Kale, Julia C. Carnevale, Erica J. Stevenson et al. · 2023
Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Violeta Serra, Anderson T. Wang, Marta Castroviejo‐Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos et al. · 2023
Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Matthew L. Hemming, Patrick D. Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson et al. · 2023
Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Matthew L. Hemming, Patrick D. Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson et al. · 2023
[Multiple primary malignancies combined with SWI/SNF complex-deficient gastric cancer: a case report and literature review].
C Lü, Xianghua Wu, Qunli Xia · 2023 · PubMed Central
Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Michael Cecchini, Janie Yue Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine et al. · 2023
Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Michael Cecchini, Janie Yue Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine et al. · 2023
Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers
Ji‐Won Kim, Jaeik Oh, Dongjun Jang, Seungjae Shin, Soojin Lee, Sang Eun Lee, Yoojin Yang, Do‐Hee Kim, Ae-Jin Choi, Hae Rim Jung et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Nongestational Trophoblastic Neoplasms Derived from Somatic Tumors or of Germ Cell Origin
Deyin Xing, Brigitte M. Ronnett · 2025 · Springer eBooks
A Case of False-Negative Results in the One-Step Nucleic Acid Amplification Assay for Sentinel Lymph Node Metastasis in Breast Cancer with Low Cytokeratin 19 Expression
Ai Koyanagi, Akinari Kakumoto, Hajime Kuroda, Shogo Baba, Mami Koketsu, Oi Harada, Yasutaka Kato, Hiroshi Nishihara, Hiroyuki Kawami · 2025 · Case Reports in Oncology
ATR inhibitors synergize with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids
Alba Zuidema, Levi Nijland, Mette Marit Vosjan, Kyah van Megesen, Bastiaan J. Viergever, Onno Kranenburg, Richard Paul Meijer · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)
Grace Y.T. Tan, Pei-Yi Lin, Li-Tzu Cheng, Yu-Sheng Tsai Yuan, Shih‐Han Huang, Chen-Hsin Albert Yu, Chao-Tsen Chen, Peter Chi, Wendy W. Hwang‐Verslues · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Case Report: Genomic characterization of a rare skull-base plasmacytoma
Hasan Alanya, Sreekar Kasturi, Kanat Yalcin, Batur Gültekin, Deepika Kumar, Natalia Samuel, Diego Samper Figuera, Ketu Mishra-Gorur, Murat Günel, Zeynep Erson-Omay et al. · 2025 · Frontiers in Oncology
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Alizée Lebeau, Athanasios Kakkos, Natacha Leroi, Vincent Bours, Katty Delbecque, Frédéric Goffin, Elodie Gonne, Christine Gennigens · 2025 · Therapeutic Advances in Medical Oncology
Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies
Minyoung Jang, Stefan M. Gysler, Nawar Latif, Emily Meichun Ko, Robert Lawrence Giuntoli, Sarah H. Kim, Fiona A. Simpkins, Dimitrios Nasioudis · 2025 · Gynecologic Oncology Reports
Additional file 1 of ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Tao Xing, Li, Li, Rao, Xiaosong, Zhao, Jing, Chen, Yiran, Ju, Gaoda, Yaping Xu, Gao, Xuan, Dong, Guilan, Xuefeng Xia et al. · 2024 · Figshare
Additional file 2 of ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Tao Xing, Li, Li, Rao, Xiaosong, Jing Zhao, Chen, Yiran, Ju, Gaoda, Yaping Xu, Gao, Xuan, Dong, Guilan, Xuefeng Xia et al. · 2024 · Figshare
Additional file 1 of Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
Chien, Wenwen, Jeffrey W Tyner, Sigal Gery, Yueyuan Zheng, Li, Li-Yan, Gopinatha Pillai, Mohan Shankar, Chehyun Nam, Bhowmick, Neil A., Lin, De-Chen, Koeffler, H. Phillip · 2023 · Figshare
Additional file 3 of ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Tao Xing, Li, Li, Rao, Xiaosong, Zhao, Jing, Chen, Yiran, Ju, Gaoda, Yaping Xu, Gao, Xuan, Dong, Guilan, Xuefeng Xia et al. · 2024 · Figshare
Additional file 1 of A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Ivana Stružinská, Nikola Hájková, Hojný, Jan, Eva Krkavcová, Romana Michálková, Jiří Dvořák, Kristýna Němejcová, Matěj, Radoslav, Laco, Jan, Drozenová, Jana et al. · 2024 · Figshare
Additional file 3 of A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Ivana Stružinská, Nikola Hájková, Hojný, Jan, Eva Krkavcová, Romana Michálková, Dvořák, Jiří, Kristýna Němejcová, Matěj, Radoslav, Laco, Jan, Drozenová, Jana et al. · 2024 · Figshare
Additional file 2 of A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Ivana Stružinská, Nikola Hájková, Hojný, Jan, Eva Krkavcová, Romana Michálková, Dvořák, Jiří, Kristýna Němejcová, Radoslav Matěj, Ján Laco, Drozenová, Jana et al. · 2024 · Figshare
Additional file 4 of A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Ivana Stružinská, Nikola Hájková, Hojný, Jan, Eva Krkavcová, Romana Michálková, Jiří Dvořák, Kristýna Němejcová, Radoslav Matěj, Ján Laco, Drozenová, Jana et al. · 2024 · Figshare
Additional file 4 of ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Tao Xing, Li, Li, Rao, Xiaosong, Zhao, Jing, Chen, Yiran, Ju, Gaoda, Yaping Xu, Gao, Xuan, Dong, Guilan, Xuefeng Xia et al. · 2024 · Figshare
Targeting miR-4653-3p/SLC25A51/SIRT3 axis to induce synthetic lethality in ARID1A-deficient colorectal cancer via blockade of DNA repair
Xin Lin, Changjie Wu, Danzhu Wu, Wenjie Qin, Yingyi Zeng, Yixian Song, Xiang Li, Joong Sup Shim, S D Liu, Aimin Li · 2026 · Journal of Translational Medicine
Impact of low replication stress on the replication program of cancer and non-tumor cells
Lilas Courtot · 2020 · theses.fr (ABES)
Marqueurs moléculaires d’intérêt pronostique et thérapeutique chez les patients atteints de lymphome à cellules du manteau
Yannick Le Bris · 2020
Utilisation de l’ADN circulant pour l’étude de l'hétérogénéité tumorale et l'évolution clonale en oncologie pédiatrique
Mathieu Chicard · 2020
Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers
Jae‐Joong Kim, Jaeik Oh, D G Jang, Seungjae Shin, Soo-Jin Lee, Sang Eun Lee, Yoojin Yang, Dohee Kim, Ae Jin Choi, Hae Rim Jung et al. · 2026 · Science Advances
ATR activity regulates DNA replication and RNA polymerase II transcription during S-phase
Jianming Wang, Sudipta Pathak, Jones, Jingwen Mao, Marco Saponaro · 2026 · iScience
Targeting epigenetic regulators induces transcription-replication conflicts to overcome ATR inhibitor resistance
Samah W. Awwad, Holly Barber, Josie Coulthard, Simon C.C. Lam, Alejandra Rojas, Nadia Gueorguieva, Michael Woods, Gabriel Balmus, Rimma Belotserkovskaya, Stephen P. Jackson · 2026 · Nucleic Acids Research
ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids
Alba Zuidema, Levi Nijland, Kyah van Megesen, Mette Marit Vosjan, Bastiaan J. Viergever, Onno Kranenburg, Richard Paul Meijer · 2026 · British Journal of Cancer
Molecular characterization of NSMP endometrial cancer and its relevance for treatment
Tarik Silk, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos · 2026 · Gynecologic Oncology
Targeting the DNA Damage Response in Cancer
Yihuan Qiao, Boyu Kang, Jian Zhang, Rui Zhang, Jipeng Li · 2026 · MedComm
Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions
Yixuan Ren, Lei Yang, Boyi Fei, Rong Guo, Junran Huang, Zhenghao Xu, Ruoran Wang, Pinqi Zhang, Dandan Cao, Pan Chen et al. · 2026 · Science China Life Sciences
BindingDB Entry 50023147: Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50007835: Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
BindingDB · 2021 · UC San Diego
BindingDB Entry 50019290: Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50021397: Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
BindingDB · 2025 · UC San Diego